Alnylam defends against Tekmira complaint, files answer and counterclaim

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, has filed an answer and counterclaim to a complaint filed by Tekmira Pharmaceuticals Corporation in the Business Litigation Session (BLS) of the Massachusetts Superior Court.

“a major scientific breakthrough that happens once every decade or so”

"Alnylam continues to believe that the complaint filed by Tekmira is without merit or foundation, and the company intends to fully defend itself in this matter," said Barry Greene, President and Chief Operating Officer of Alnylam. "Our focus remains on the advancement of RNAi therapeutics to patients and execution on our clinical programs."


 Alnylam Pharmaceuticals


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
You might also like...
Immune particles from llama blood could offer protection against several COVID-19 variants